VBIV VBIV

VBI Vaccines Stock Price

0.4852
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
0.4852
Volume 0
Bid Price 0.4951
Ask Price 0.509
News -
Day High

Low
0.48

52 Week Range

High
2.75

Day Low
Company Name Stock Ticker Symbol Market Type
VBI Vaccines Inc VBIV NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 0.4852 19:00:00
Open Price Low Price High Price Close Price Prev Close
0.4852
Trades Volume Avg Volume 52 Week Range
0 0 - 0.48 - 2.75
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.4852 USD

Period:

Draw Mode:

VBI Vaccines Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 125.31M 258.26M 191.22M $ 631.00k $ - -0.27 -1.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 0.60%

more financials information »

VBI Vaccines News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical VBIV Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.60930.630.480.52194931,684,605-0.1241-20.37%
1 Month0.670.6990.480.57431,068,013-0.1848-27.58%
3 Months0.820.850.480.6610208850,906-0.3348-40.83%
6 Months0.94891.350.480.80615631,511,931-0.4637-48.87%
1 Year2.392.750.481.351,943,754-1.90-79.7%
3 Years0.817.240.482.795,081,776-0.3248-40.1%
5 Years4.247.240.452.603,431,108-3.75-88.56%

VBI Vaccines Description

VBI Vaccines Inc is a US-based commercial-stage, the biopharmaceutical company which is engaged in developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology. The company manufactures Sci-B-Vac product which is a hepatitis B (HBV) vaccine for adults, children, and newborns. Its products include Virus-Like Particle which is vaccine platform which allows for the design of enveloped virus-like particle vaccines that closely mimic the target viruses. The company operates through the single segment being Developing vaccines to address unmet needs in infectious disease and immuno-oncology.